Literature DB >> 9972318

In vivo prevention of cyclophosphamide-induced Ca2+ dependent damage of rat heart and liver mitochondria by cyclosporin A.

I A al-Nasser1.   

Abstract

The use of Cyclophosphamide, an anti-cancer and immunosuppressant drug, is accompanied by a number of side effects. Rats injected with a single dose of cyclophosphamide (200 mg kg-1 body weight) showed an increase in the levels of serum glutamate-oxaloacetate transaminase, serum glutamate-pyruvate transaminase, glucose-6-phosphate dehydrogenase and creatine phosphokinase isoenzyme by 53, 24, 55 and 135%, respectively. Also the ability of heart or liver mitochondria to retain accumulated Ca2+ and tetraphenylphosphonium ion was sharply affected in treated rats. Rats injected with the same dose of cyclophosphamide plus cyclosporin A (500 micrograms kg-1 body weight) showed reduction in the levels of those enzymes by about 44, 21, 43 and 57%, respectively compared to cyclophosphamide-treated rats. Cyclosporin A treatment also restored mitochondrial ability to retain accumulated Ca2+ and tetraphenyl phosphonium ions nearly to the level of untreated rats. We suggest that cyclophosphamide induced cardio and hepatotoxicity by increasing heart and liver inner mitochondrial membrane permeability to Ca2+. The protective effect of cyclosporin A against cyclophosphamide-induced damage also support this suggestion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9972318     DOI: 10.1016/s1095-6433(98)10135-6

Source DB:  PubMed          Journal:  Comp Biochem Physiol A Mol Integr Physiol        ISSN: 1095-6433            Impact factor:   2.320


  7 in total

1.  Mitigation of oxidative stress in cyclophosphamide-challenged hepatic tissue by DL-alpha-lipoic acid.

Authors:  Elangovan Selvakumar; Chidambaram Prahalathan; Yenjerla Mythili; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

2.  A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy.

Authors:  Gian Piero Carboni
Journal:  Am J Cardiovasc Dis       Date:  2012-10-25

3.  Nitrergic response to cyclophosphamide treatment in blood and bone marrow.

Authors:  Kevorkian G A; Alchujyan N Kh; Movsesyan N H; Hayrapetyan H L; Guevorkian A G; Ohanyan R M; Dagbashyan S S
Journal:  Open Biochem J       Date:  2008-06-03

4.  Protective Effects of Fullerene C60 Nanoparticles and Virgin Olive Oil against Genotoxicity Induced by Cyclophosphamide in Rats.

Authors:  Fayza M Aly; Amnah Othman; Mohie A M Haridy
Journal:  Oxid Med Cell Longev       Date:  2018-07-15       Impact factor: 6.543

Review 5.  The Role of Antioxidants in Ameliorating Cyclophosphamide-Induced Cardiotoxicity.

Authors:  Muluken Altaye Ayza; Kaleab Alemayehu Zewdie; Bekalu Amare Tesfaye; Dawit Zewdu Wondafrash; Abera Hadgu Berhe
Journal:  Oxid Med Cell Longev       Date:  2020-05-10       Impact factor: 6.543

6.  Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy.

Authors:  Constance C F M J Baaten; Floor C J I Moenen; Yvonne M C Henskens; Frauke Swieringa; Rick J H Wetzels; René van Oerle; Harry F G Heijnen; Hugo Ten Cate; Graham P Holloway; Erik A M Beckers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

7.  Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature.

Authors:  Panpan Qian; Chun Hong Peng; Xianwei Ye
Journal:  Respir Med Case Rep       Date:  2019-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.